Human IgGs and Endothelial Function in Vivo in Humans
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Endothelial dysfunction and insulin resistance play a key role in the onset and development
of atherosclerosis, cardiovascular diseases, and diabetes. Data in mice models have recently
demonstrated that circulating immunoglobulins G (IgG) could be involved in the process.
Patients with common variable immunodeficiency (CVID), who are characterized by low
circulating levels of IgG, might represent an ideal model to clarify the role played in vivo
in humans by circulating IgG. Polyclonal IgG, obtained from multiple donors, given
intravenously (IVIgG), are used to treat various immunodeficiencies and autoimmune diseases,
including CVID. By using this disease and its treatment by IVIgG as a model, aim of the
current study is to clarify whether IgG affect endothelial function and insulin sensitivity
in humans in vivo and whether the action of IgG on the endothelium involves a direct
interaction with the endothelial cells.